The long-standing focus on amyloid plaques and tau tangles as the primary targets in Alzheimer's research may be incomplete. A growing body of evidence now positions disrupted lipid metabolism as a fundamental upstream regulator of the neuroinflammatory cascades that accelerate neurodegeneration — a reframing with real implications for prevention strategies and drug development.
This review, published in Frontiers in Immunology, synthesizes recent research on how lipid dysregulation shapes Alzheimer's pathogenesis. The brain is among the body's most lipid-dense organs, and its function depends on tightly maintained lipid homeostasis. When that balance breaks down — through shifts in fatty acid composition, altered apolipoprotein E (ApoE) isoform activity, or reduced lipoprotein lipase function — microglial cells shift into pro-inflammatory activation states that amplify amyloid aggregation and tau pathology. Polyunsaturated fatty acids and lipid-derived signaling molecules exhibit notably dual roles: they can either suppress or intensify inflammatory cascades depending on context, affecting oxidative stress and microglial polarization simultaneously. The review also identifies systemic contributors, including obesity, insulin resistance, and gut microbiota dysbiosis, as amplifiers of central nervous system lipid imbalance through cytokine signaling and blood-brain barrier disruption.
What makes this synthesis particularly timely is the convergence of metabolic and neurological research streams. The ApoE4 allele — the strongest known genetic risk factor for late-onset Alzheimer's — is fundamentally a lipid transport gene, yet its inflammatory consequences have historically been underemphasized in clinical thinking. This review draws an explicit mechanistic line from peripheral metabolic dysfunction to central neuroinflammation, reinforcing the concept that conditions like metabolic syndrome may predispose the brain to Alzheimer's via lipid-mediated inflammatory priming. As a review rather than an original trial, the findings are synthesis-level rather than causal, and the proposed therapeutic strategies targeting lipid-inflammation axes remain largely preclinical. Still, the framework offered here is incrementally paradigm-clarifying — nudging Alzheimer's research toward metabolic and inflammatory targets that existing lipid-modulating compounds could plausibly address.